Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. reported revenue of $0 for the fiscal year ended Dec 31, 2025. Net income was a loss of $1.13B (prior year: −$600.09M). At the end of that fiscal year the company reported total assets of $2.35B and shareholders' equity of $1.63B.
Revenue
$0
FY ended Dec 2025
Net income
−$1.13B
FY ended Dec 2025
Diluted EPS
−$5.95
USD per share
Total assets
$2.35B
At Dec 31, 2025
Equity
$1.63B
At Dec 31, 2025
Shares outstanding
214M
As of Jul 31, 2026
Explore Revolution Medicines, Inc.'s filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Aug 5, 2026
- 10-QFiled May 6, 2026
- 10-KFiled Feb 25, 2026
- 10-QFiled Nov 5, 2025
- 10-QFiled Aug 6, 2025
- 10-QFiled May 7, 2025
Source: SEC EDGAR XBRL company facts for CIK 1628171 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.